BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12165855)

  • 21. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
    Ramani P; Cowell JK
    J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
    Fukuzawa R; Heathcott RW; More HE; Reeve AE
    J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function.
    Hewitt SM; Saunders GF
    Anticancer Res; 1996; 16(2):621-6. PubMed ID: 8687106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells.
    Glienke W; Maute L; Wicht J; Bergmann L
    Eur J Cancer; 2009 Mar; 45(5):874-80. PubMed ID: 19196508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
    Grubb GR; Yun K; Reeve AE; Eccles MR
    Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splicing of exon 5 in the WT1 gene is disrupted in Wilms' tumour.
    Simms LA; Algar EM; Smith PJ
    Eur J Cancer; 1995 Dec; 31A(13-14):2270-6. PubMed ID: 8652255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.
    Siehl JM; Reinwald M; Heufelder K; Menssen HD; Keilholz U; Thiel E
    Ann Hematol; 2004 Dec; 83(12):745-50. PubMed ID: 15340762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
    Han Y; San-Marina S; Yang L; Khoury H; Minden MD
    Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.
    Morris MR; Hesson LB; Wagner KJ; Morgan NV; Astuti D; Lees RD; Cooper WN; Lee J; Gentle D; Macdonald F; Kishida T; Grundy R; Yao M; Latif F; Maher ER
    Oncogene; 2003 Oct; 22(43):6794-801. PubMed ID: 14555992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Inhibitory effect of WT1 gene isoform transfection on proliferation of leukemia cell line NB4].
    Shen HL; Chen ZX; Wang W; Cen JN; Hu SY; Zhao Y
    Ai Zheng; 2006 Feb; 25(2):163-9. PubMed ID: 16480579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.
    Tatsumi N; Oji Y; Tsuji N; Tsuda A; Higashio M; Aoyagi S; Fukuda I; Ito K; Nakamura J; Takashima S; Kitamura Y; Miyai S; Jomgeow T; Li Z; Shirakata T; Nishida S; Tsuboi A; Oka Y; Sugiyama H
    Int J Oncol; 2008 Mar; 32(3):701-11. PubMed ID: 18292948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
    Iben S; Royer-Pokora B
    Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
    Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
    Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A gene expression signature for relapse of primary wilms tumors.
    Li W; Kessler P; Yeger H; Alami J; Reeve AE; Heathcott R; Skeen J; Williams BR
    Cancer Res; 2005 Apr; 65(7):2592-601. PubMed ID: 15805255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
    Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
    Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour.
    Liu WG; Gu WZ; Zhou YB; Tang HF; Li MJ; Ma WX
    Eur J Clin Invest; 2008 Dec; 38(12):931-8. PubMed ID: 19021718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of possible WT1 RNA processing in primary Wilms tumors.
    Gunning KB; Cohn SL; Tomlinson GE; Strong LC; Huff V
    Oncogene; 1996 Sep; 13(6):1179-85. PubMed ID: 8808692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.